ESMO 2016 Report — Breast Cancer

Highlights of the latest treatments

At this year's European Society of Medical Oncology (ESMO) congress — held October 7–11 in Copenhagen, Denmark — investigators described the latest findings in cancer research. NEJM Journal Watch Oncology and Hematology Editor-in-Chief William J. Gradishar, MD, was on hand to review key presentations of new breast cancer therapies. All abstracts can be viewed in the ESMO 2016 congress library).

CDK Inhibition for ER-Positive, HER2-Negative Metastatic Breast Cancer

The areas of greatest interest in managing estrogen receptor (ER)-positive, metastatic breast cancer include enhancing the effect of endocrine agents and overcoming the inevitable development of drug resistance. During the past couple of years, we have seen the introduction of agent…

Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)